Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
retifanlimab + carboplatin + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Retifanlimab + carboplatin + nab-paclitaxel** is a three-drug combination regimen used as first-line therapy for advanced or metastatic squamous cell carcinoma of the anal canal (SCAC). Retifanlimab is a humanized monoclonal antibody that targets programmed cell death protein-1 (PD-1), functioning as an immune checkpoint inhibitor[1][3]. Carboplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks causing apoptosis. Nab-paclitaxel (albumin-bound paclitaxel) is a microtubule inhibitor delivered by albumin nanoparticles, enabling increased intratumoral concentrations and antitumor activity compared to solvent-based paclitaxel[2][4]. This combination demonstrated improved progression-free survival and overall response rate compared to chemotherapy alone in phase III trials for advanced SCAC[3].
- Other names
- retifanlimab-dlwr + carboplatin + nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on retifanlimab + carboplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on retifanlimab + carboplatin + nab-paclitaxel.